Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $22.00 | Buy | H.C. Wainwright |
| 7/25/2024 | $21.00 | Buy | H.C. Wainwright |
| 7/27/2023 | Sector Outperform | Scotiabank | |
| 4/17/2023 | $38.00 | Buy | BTIG Research |
| 7/19/2022 | $26.00 | Mkt Outperform | JMP Securities |
| 11/24/2021 | $40.00 | Outperform | SVB Leerink |
| 11/23/2021 | $38.00 | Buy | BTIG Research |
| 11/23/2021 | Outperform | Cowen |
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025. "I am pleased to welcome Teresa to our Board of Directors," said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. "She is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology." "I am excit
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "Throughout the first quarter of 2024, the Company made significant progress
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)
SCHEDULE 13D/A - Aura Biosciences, Inc. (0001501796) (Subject)
8-K - Aura Biosciences, Inc. (0001501796) (Filer)
424B5 - Aura Biosciences, Inc. (0001501796) (Filer)
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying warrants to purchase shares of its common stock. All of the shares of common stock, pre-funded warrants and accompanying common stock warrants to be sold in the offering will be offered by Aura. The offering is subject to market c
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Financial and Business Officer BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2025, and provided recent business highlights. "Aura has started 2025 with strong momentum, making meaningful strides across both our ocular and urologi
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
4 - Aura Biosciences, Inc. (0001501796) (Issuer)
3 - Aura Biosciences, Inc. (0001501796) (Issuer)
H.C. Wainwright resumed coverage of Aura Biosciences with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Aura Biosciences with a rating of Buy and set a new price target of $21.00
Scotiabank initiated coverage of Aura Biosciences with a rating of Sector Outperform